1 7. Promotion of medicines Pharmacy Admin and Practice 4.

Slides:



Advertisements
Similar presentations
Evidence-based Dental Practice Developing guidelines or clinical recommendations Slide #1 This lecture follows the previous online lecture on evidence.
Advertisements

Understanding and Responding to Pharmaceutical Promotion
1 Medicare Part D: Cost Management Issues Jack Hoadley Research Professor Georgetown University Health Policy Institute Families USA Health Action 2005.
4 th Meeting of the EC International Dialogue on Bioethics Copenhagen, June 19 th, 2012 Large research and medical databases in clinical and research multi-centred.
Judging Web Validity Can you trust this site? Adapted from Dr. Ramesh Mehay Course Organiser, Bradford.
MSCG Training for Project Officers and Consultants: Project Officer and Consultant Roles in Supporting Successful Onsite Technical Assistance Visits.
Slides prepared by Joe Rosagrata
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Medication Management
© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Introduction to Drug Information Services Ch.#1. An introductory course to teach the students basic principles of DI retrieval. Designed to help students.
HIGH COUNCIL FOR ECONOMY, INDUSTRY, ENERGY AND TECHNOLOGIES 1 Metrology policies to foster the competitiveness of industry J.F. Magaña.
Drug Promotion And Dealing With The ‘Reps’ Neena Lakhani.
Chapter 14 Fraud Risk Assessment.
The Changing Regulatory Environment for Industry Support The accreditation bodies’ point of view. Ian Starke (UK)
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
TBS November 4, |1 | AMR and appropriate use of antimicrobials Nicola Magrini and Jane Robertson Policy, Access and Use Team, EMP TBS 4 November.
Clinical Pharmacy Basma Y. Kentab MSc..
External Influences on Prescribing Practice Karen Ford.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Role of Pharmacist in Malaria Control
INRUD International Network for Rational Use of Drugs.
Ethical Criteria for Promotion of Medicines Technical Briefing Seminar 21 September 2006 Dr Guitelle Baghdadi, World Health Organization, Geneva.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Medicines Transparency Alliance05/09/2015 Medicine Promotion Robert Louie P. So, MD Program Manager DOH - National Center for Pharmaceutical Access and.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
“Delivering Therapeutic Agents” - Marketing and Communication Strategies of Drug Companies Safura Nantogmah.
Clinical Pharmacy Part 2
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
Medicines Transparency Alliance14/10/ Medicines promotion: innovative tools to promote rational use Carole Piriou Project officer Rational use of.
+ Conflict of Interest in Physician-Industry Relationships.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
How commercial promotion affects the use of medicines: from Evidence to Action Andrew Herxheimer, Joel Lexchin.
Promoting Rational Drug Use in the Community What influences drug use by consumers.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Promoting Drug and Therapeutics Committees in the Developing World
Origin and Process of Utah Guidelines Anna Fondario, MPH Utah Department of Health Violence and Injury Prevention Program.
Development and Implementation of Good Pharmacy Practice Standards in Developing Countries Author: Frokjaer B, International Pharmaceutical Federation.
Understanding and responding to pharmaceutical promotion: A practical guide  Americas  Europe  Western Pacific  Eastern Mediterranean  Africa  South-East.
Student Learning Outcomes (Pharmacy) Susan S. S. Ho School of Pharmacy Faculty of Medicine The Chinese University of Hong Kong 9 September 2007.
Drug & Poison Control center
The WHO/ HAI Drug Promo Database Andrew Herxheimer, Joel Lexchin.
Ethics Case 1 Remonte. Rivera, K., Sagayaga. Siy. Talan.
Trade & Access to Medicines in India Centre for Trade & Development
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Positions of pharmaceutical companies Analysis of the websites of the three world’s largest PCs: Pfizer, Roche and Novartis.
From Jan 1, no freebies for docs from pharma firms.
Documentation in Practice Dept. of Clinical Pharmacy.
CIS 170 MART Teaching Effectively/cis170mart.com FOR MORE CLASSES VISIT HCA 497 MART Inspiring Minds/hca497mart.com FOR MORE CLASSES.
Khaldoon AlKhaldi, MD Disaster medicine / Pre-Hospital care & International EMS Fellow BIDMC Harvard Medical schoo l Evolution of research production of.
Disclosure UK Talking about Transparency.
Implementation of Clinical Guidelines Author: dr. Martin Rusnák
Introduction to Clinical Pharmacy
Integrating Clinical Pharmacy into a wider health economy
Disclosure UK Talking about Transparency.
Reading Research Papers-A Basic Guide to Critical Analysis
Impact of a public education program on promoting rational use of medicines:
Implementation Considerations
Pharmacy practice experience I
AGREEMENT FOR TRANSPARENCY The Case of Mexico
APOLLOJAMES LECTURER NANDHA COLLEGE OF PHARMACY
National Medicines Policies
Presentation transcript:

1 7. Promotion of medicines Pharmacy Admin and Practice 4

2 OUTCOMES- Promotion of medicines Interpret drug promotion activities of pharmaceutical industries Analyze the requirement of WHO ethical criteria for medicinal drug promotion Point out the importance of Equal Time Presentation

3 Drug Promotion Advertisements for medicines Sales representatives / drug detailers Free samples Use of opinion leaders Sponsored conferences and seminars Promotional research funded by companies to stimulate sales Gifts Use of the Internet to promote medicines Industry-funded pharmacy or scientific journals Industry-funded research published in peer-reviewed journals

4 Med-reps and irrational medicine use in sub- Saharan Africa 4/msg00048.php Fellow e-druggers, I feel saddened to report of several instances where prescriptions for some particular slow-moving medicines are received in pharmacies from medical prescribers only when the med-reps visit the doctors in their consulting rooms. What is prescribed at any point in time depends much on which company's rep came around, and a discerning mind can almost always ascertain which product rep was around from the most recent prescription patterns.

5 There seems to be an over-reliance on sometimes-biased information (intended to maximize product sales) from pharmaceutical promoters and marketers, and the medics feel too arrogant in many cases to clarify or obtain information from resident Pharmacists, although most of the latter too may be guilty of not being up- to -date on current drug issues. Often, there is some element of pecuniary consideration involved-the reps are most probably more effective than resident Pharmacists because they not only offer information but also pass on their companies good-will, which is quite an obvious added advantage in a financially desperate environment. May I further add that this observation is not limited to my institution alone. Olutayo Adetokunbo Moronkeji, B. Pharm., MPSN, MNIM, CEDP (Hons.) Deputy Chief Pharmacist, Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), NIGERIA.

6 BMJ: Say no to the free lunch Are you a pig or a weasel? Or do you consider yourself above all that? When the BMJ published a special issue on the links between doctors and drug companies in 2003, the cover showed pigs in white coats lunching and golfing with weasel drug reps. The power of drug companies to buy influence over every key group in health care-doctors, charities, patient groups, journalists, politicians-has clearly shocked a UK parliamentary committee (p 855). It should shock us all. Can we console ourselves that companies' lavish spending on research and marketing, which far outstrips spending on independent research and drug information, leads to truly innovative treatments? No, says the committee's report. Can we rely on regulatory bodies to keep the industry in check? No, again.

7 Issues of intense concern Drug promotion – effectively monitored in only 52 of 102 countries for which relevant data are available Too often, medical representatives of pharmaceutical companies are the primary source of drug information for prescribers Most prescribers are not trained to evaluate such information critically Continuing education in good prescribing is unavailable Access to Medicine Information Center?

8 Responsible drug promotion encouraged Through advocacy, promotion of adherence to the WHO Ethical Criteria for Medicinal Drug Promotion, and support for development of national guidelines for drug promotion and national measures to prevent and monitor perverse incentives for prescribers and dispensers. mon.shtml

9 Evaluation of the implementation of WHO ethical criteria (WHO - EC) for medicinal drug promotion in Indonesia Most of adverts in medical journals as well as in the public magazines do not comply with the ethical criteria, e.g. do not include the generic name of active ingredient, do not include precautions or warnings. Similar results for public advertisements broadcasted on radio and television programs. Most respondents, either medical practitioners or medical representatives, did not know about the WHO Ethical Criteria for Medicinal Drug Promotion nor the existing regulation on pharmaceutical promotion. This study shows the obvious lack in the dissemination of the WHO Ethical Criteria for Medicinal Drug Promotion, and in the enforcement and monitoring of the existing regulation despite their formal promulgation.

10 Teaching critical appraisal of medicinal drug promotions in a medical school Objective: To determine the effect of teaching critical appraisal of medicinal drug promotion on the ability of medical students to identify violations of existing guidelines for drug promotion. Generic labelling Safety and efficacy claims Pharmacological information Documentation of claims

11 Role of WHO Rational Use of Medicines Special activities: Promoting rational Drug Use: A CD-ROM Training ProgramPromoting rational Drug Use: ICIUM - International Rational Drug Use ConferenceICIUM - International Rational Drug Use Conference

12 Role of WHO Ethical Criteria for medicinal drug promotion - What attitudes do people (professional and lay) have to promotion? - What impact does pharmaceutical promotion have on attitudes and knowledge? - What impact does pharmaceutical promotion have on behaviour? - What interventions have been tried to counter promotional activities, and with what results?

13 Who Developed The Website and Database? The development of this website was co- ordinated by the WHO Department of Essential Drugs & Medicines Policy and Health Action International Europe. WHY? There continues to be an imbalance between commercially produced drug information and independent, comparative, scientifically validated and up-to-date information on drugs for prescribers, dispensers and consumers.

14 WHAT ARE THE OBJECTIVES OF THE WEBSITE Document the volume of inappropriate drug promotion in developing and developed countries; Document the impact of inappropriate promotion on health; Identify topics that are not covered by present studies; Formulate recommendations for needed research; Provide information about tools that can be used to teach health professionals about drug promotion; Provide tools to monitor drug promotion; Promote networking of groups and individuals concerned about promotion by providing links through the website.

15 Hospital policy on pharmaceutical promotion Many prescribers-medical reps are primary source of information on new medicines Promoting drugs-Biased? Train to analyze content of promotional material WHO criteria-basis for developing measures and guidelines on drug promotion Reliable, accurate, truthful,informative, balanced, up-to-date, capable of substantiation and in good taste

16 Equal Time Presentation Reps are required to submit their material in advance Hospital pharmacist actively reviews material Meeting arranged at which rep is invited to present info to all doctors, followed by EQUAL TIME PRESENTATION by the pharmacist to comment on the materials presented Meeting opened for questions and discussion-debate merits of a new medicine – for a BALANCED perspective on that medicine

17 Role of PTC EQUAL TIME PRESENTTAION BAN MEDICAL REPS ENTIRELY (COULD BE NON PRODUCTIVE) PREVENT DISPLAY OF INAPPROPRIATEPOSTERS, ADVERTISING MEDIICNES AIMED AT CONSUMERS

18 IMPORTANT WEBSITE sp?keyday=day%201 TB: Global Issues in TB Drug Provision Multi-Country Participatory Evaluation of the Implementation of the WHO Ethical Criteria for Medicinal Drug Promotion: Networking Tools for Monitoring and Evaluation Developing Tools for Monitoring and Evaluating Unethical Drug Promotion in Thailand The Interface between Policy, Politics, and Practice